The drug’s star fell in October when the Basel-based company announced it had failed a pair of trials in moderate asthmatic patients.
Now, fevipiprant has flopped in two additional studies in moderate-to-severe patients, spelling the end to its development for asthma.
Novartis chief drug developer John Tsai had continued to hold out hope that the trial failures in moderate patients were a fluke and that the drug would be more effective in patients hit harder by the respiratory disorder.
Instead, fevipiprant failed to reduce exacerbations — an acute episode of symptoms growing worse — compared to a placebo over a 52-week treatment period for either the 150 mg or 450 mg dose of the drug.
“The totality of these results do not support further development of fevipiprant in asthma,” said Novartis, which had hoped the medicine would become an alternative for patients for whom existing therapies like inhaled corticosteroids did not bring sufficient improvement.
Despite the failure, Novartis continues to hold out hope that it has about two dozen potential blockbuster medicines — those that will exceed $1 billion in annual sales — in its pipeline.